{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T15:59:07Z","timestamp":1793721547905,"version":"4.6.1"},"reference-count":172,"publisher":"Bentham Science Publishers Ltd.","issue":"33","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2019,11,19]]},"abstract":"<jats:sec><jats:title>:<\/jats:title><jats:p>In the brain, acetylcholine (ACh) is regarded as one of the major neurotransmitters. During the advancement of Alzheimer's disease (AD) cholinergic deficits occur and this can lead to extensive cognitive dysfunction and decline. Acetylcholinesterase (AChE) remains a highly feasible target for the symptomatic improvement of AD. Acetylcholinesterase (AChE) remains a highly viable target for the symptomatic improvement in AD because cholinergic deficit is a consistent and early finding in AD. The treatment approach of inhibiting peripheral AChE for myasthenia gravis had effectively proven that AChE inhibition was a reachable therapeutic target. Subsequently tacrine, donepezil, rivastigmine, and galantamine were developed and approved for the symptomatic treatment of AD. Since then, multiple cholinesterase inhibitors (ChEIs) have been continued to be developed. These include newer ChEIs, naturally derived ChEIs, hybrids, and synthetic analogues. In this paper, we summarize the different types of ChEIs which are under development and their respective mechanisms of actions.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1381612825666191008103141","type":"journal-article","created":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T16:01:23Z","timestamp":1570550483000},"page":"3519-3535","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":115,"title":["Cholinesterase Inhibitors for Alzheimer's Disease: Multitargeting Strategy Based on Anti-Alzheimer's Drugs Repositioning"],"prefix":"10.2174","volume":"25","author":[{"given":"Md. Tanvir","family":"Kabir","sequence":"first","affiliation":[{"name":"Department of Pharmacy, BRAC University, Dhaka, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Sahab","family":"Uddin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Southeast University, Dhaka, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mst. Marium","family":"Begum","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, East West University, Dhaka, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanmugam","family":"Thangapandiyan","sequence":"additional","affiliation":[{"name":"Department of Zoology, Bharathiar University, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Sohanur","family":"Rahman","sequence":"additional","affiliation":[{"name":"Graduate School of Innovative Life Science, University of Toyama, Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotfi","family":"Aleya","sequence":"additional","affiliation":[{"name":"Chrono-Environnement Laboratory, CNRS 6249, Bourgogne Franche-Comt\u00e9 University, Besan\u00e7on, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijo","family":"Mathew","sequence":"additional","affiliation":[{"name":"Division of Drug Design and Medicinal Chemistry Research Lab, Department of Pharmaceutical Chemistry, Ahalia School of Pharmacy, Palakkad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muniruddin","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Daffodil International University, Dhaka, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George E.","family":"Barreto","sequence":"additional","affiliation":[{"name":"Instituto de Ciencias Biom\u00e9dicas, Universidad Aut\u00f3noma de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghulam Md.","family":"Ashraf","sequence":"additional","affiliation":[{"name":"King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnagi.2018.00004","volume":"10","author":"Uddin M.S.","year":"2018","unstructured":"Uddin M.S.; Stachowiak A.; Mamun A.A.; Autophagy and Alzheimer\u2019s disease: from molecular mechanisms to therapeutic implications. Front Aging Neurosci 2018,10,1-18","journal-title":"Front Aging Neurosci"},{"key":"ref=2","year":"2019","unstructured":"Alzheimer\u2019s Disease Facts and Figures Includes a Special Report on Alzheimer\u2019s Detection in the Primary Care Setting: Connecting Patients and Physicians 2019"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/WNL.0b013e31828726f5","volume":"80","author":"Hebert L.E.","year":"2013","unstructured":"Hebert L.E.; Weuve J.; Scherr P.A.; Evans D.A.; Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology 2013,80(19),1778-1783","journal-title":"Neurology"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1159\/000481812","volume":"25","author":"Uddin M.S.","year":"2018","unstructured":"Uddin M.S.; Al Mamun A.; Asaduzzaman M.; Spectrum of disease and prescription pattern for outpatients with neurological disorders: an empirical pilot study in Bangladesh. Ann Neurosci 2018,25(1),25-37","journal-title":"Ann Neurosci"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.9734\/INDJ\/2016\/26317","volume":"8","author":"Uddin M.","year":"2016","unstructured":"Uddin M.; Mamun A.; Sarwar M.; Medicine that causes memory loss: risk of neurocognitive disorders. Int Neuropsychiatr Dis J 2016,8,1-18","journal-title":"Int Neuropsychiatr Dis J"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1007\/s12035-018-1237-z","volume":"56","author":"Uddin M.S.","year":"2019","unstructured":"Uddin M.S.; Kabir M.T.; Al Mamun A.; Abdel-Daim M.M.; Barreto G.E.; Ashraf G.M.; APOE and Alzheimer\u2019s disease: evidence mounts that targeting APOE4 may combat Alzheimer\u2019s pathogenesis. Mol Neurobiol 2019,56(4),2450-2465","journal-title":"Mol Neurobiol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/psyg.12368","volume":"19","author":"Uddin M.S.","year":"2019","unstructured":"Uddin M.S.; Mamun A.A.; Takeda S.; Sarwar M.S.; Begum M.M.; Analyzing the chance of developing dementia among geriatric people: a cross-sectional pilot study in Bangladesh. Psychogeriatrics 2019,19(2),87-94","journal-title":"Psychogeriatrics"},{"key":"ref=8","first-page":"315","volume":"71","author":"Ito N.","year":"1996","unstructured":"Ito N.; Clinical aspects of dementia. Hokkaido Igaku Zasshi 1996,71(3),315-320","journal-title":"Hokkaido Igaku Zasshi"},{"key":"ref=9","year":"2000","unstructured":"American Psychiatric Association American Psychiatric Association. Task Force on DSM-IV. (2000) Diagnostic and statistical manual of mental disorders: DSM-IV-TR. American Psychiatric Association2000","journal-title":"American Psychiatric Association"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/0165-6147(91)90609-V","volume":"12","author":"Hardy J.","year":"1991","unstructured":"Hardy J.; Allsop D.; Amyloid deposition as the central event in the aetiology of Alzheimer\u2019s disease. Trends Pharmacol Sci 1991,12(10),383-388","journal-title":"Trends Pharmacol Sci"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/0896-6273(91)90052-2","volume":"6","author":"Selkoe D.J.","year":"1991","unstructured":"Selkoe D.J.; The molecular pathology of Alzheimer\u2019s disease. Neuron 1991,6(4),487-498","journal-title":"Neuron"},{"key":"ref=12","author":"Uddin M.S.","year":"2019","unstructured":"Uddin M.S.; Kabir M.T.; Oxidative stress in Alzheimer\u2019s disease: molecular hallmarks of underlying vulnerability. Biological, Diagnostic and Therapeutic Advances in Alzheimer\u2019s Disease 2019","journal-title":"Biological, Diagnostic and Therapeutic Advances in Alzheimer\u2019s Disease"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"Hardy J.","year":"2002","unstructured":"Hardy J.; Selkoe D.J.; The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science 2002,297(5580),353-356","journal-title":"Science"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fnins.2018.00025","volume":"12","author":"Kametani F.","year":"2018","unstructured":"Kametani F.; Hasegawa M.; Reconsideration of amyloid hypothesis and tau hypothesis in Alzheimer\u2019s disease. Front Neurosci 2018,12,25","journal-title":"Front Neurosci"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2161-0460.1000245","volume":"6","author":"Uddin M.S.","year":"2016","unstructured":"Uddin M.S.; Asaduzzaman M.; Mamun A.A.; Neuroprotective activity of Asparagus racemosus Linn. against ethanol- induced cognitive impairment and oxidative stress in rats brain: auspicious for controlling the risk of Alzheimer\u2019s Disease. J Alzheimer\u2019s Dis Park 2016,6,1-10","journal-title":"J Alzheimer\u2019s Dis Park"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2155-9562.1000397","volume":"07","author":"Uddin M.S.","year":"2016","unstructured":"Uddin M.S.; Haque A.; Al Mamun A.; Searching the linkage between high fat diet and Alzheimer\u2032s disease: a debatable proof stand for ketogenic diet to alleviate symptoms of Alzheimer\u2032s patient with APOE \u03b54 allele. J Neurol Neurophysiol 2016,07,1-9","journal-title":"J Neurol Neurophysiol"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"50","DOI":"10.6000\/2292-2598.2017.05.02.3","volume":"5","author":"Rahman A","year":"2017","unstructured":"Rahman A; Haque A; Uddin M; In vitro screening for antioxidant and anticholinesterase effects of Uvaria littoralis Blume.: a nootropic phytotherapeutic remedy. J Intellect Disabil - Diagnosis Treat 2017,5,50-60","journal-title":"J Intellect Disabil - Diagnosis Treat"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.6000\/2292-2598.2017.05.04.6","volume":"5","author":"Uddin MS","year":"2018","unstructured":"Uddin MS; Mamun AAl, Kabir MT, et al. Neurochemistry of neurochemicals: messengers of brain functions. J Intellect Disabil - Diagnosis Treat 2018,5,137-51","journal-title":"J Intellect Disabil - Diagnosis Treat"},{"key":"ref=19","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/728983","volume":"2012","author":"Mehta M.","year":"2012","unstructured":"Mehta M.; Adem A.; Sabbagh M.; New acetylcholinesterase inhibitors for Alzheimer\u2019s disease. Int J Alzheimers Dis 2012,2012","journal-title":"Int J Alzheimers Dis"},{"key":"ref=20","author":"Uddin M.S.","year":"2018","unstructured":"Uddin M.S.; Amran M.S.; Handbook of Research on Critical Examinations of Neurodegenerative Disorders 2018","journal-title":"Handbook of Research on Critical Examinations of Neurodegenerative Disorders"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/B978-1-4160-6231-8.10054-6","volume":"362","author":"Henry W.","year":"2010","unstructured":"Henry W.; Querfurth M.D.; Ph D.; Frank M.; LaFerla P.; Mechanisms of Alzheimer\u2019s disease. N Engl J Med 2010,362(362),329-344","journal-title":"N Engl J Med"},{"key":"ref=22","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.78252","author":"Ashraf G.M.","year":"2019","unstructured":"Ashraf G.M.; Uddin M.S.; Advances in Dementia Research 2019","journal-title":"Advances in Dementia Research"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12035-019-01660-3","author":"Hossain M.F.","year":"2019","unstructured":"Hossain M.F.; Uddin M.S.; Uddin G.M.S.; Melatonin in Alzheimer\u2019s disease: a latent endogenous regulator of neurogenesis to mitigate Alzheimer\u2019s neuropathology. Mol Neurobiol 2019,1-22","journal-title":"Mol Neurobiol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S1474-4422(11)70072-2","volume":"10","author":"Barnes D.E.","year":"2011","unstructured":"Barnes D.E.; Yaffe K.; The projected effect of risk factor reduction on Alzheimer\u2019s disease prevalence. Lancet Neurol 2011,10(9),819-828","journal-title":"Lancet Neurol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1381612825666191011102444","volume":"25","author":"Kabir M.T.","year":"2019","unstructured":"Kabir M.T.; Abu Sufian M.; Uddin M.S.; NMDA receptor antagonists: repositioning of memantine as multitargeting agent for Alzheimer\u2019s therapy. Curr Pharm Des 2019,25,1-13","journal-title":"Curr Pharm Des"},{"key":"ref=26","author":"Uddin M.S.","year":"2019","unstructured":"Uddin M.S.; Upaganlawar A.B.; Oxidative stress and antioxidant defense: biomedical value in health and diseases 2019","journal-title":"Oxidative stress and antioxidant defense: biomedical value in health and diseases"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1161\/HYP.0000000000000053","volume":"68","author":"Iadecola C","year":"2016","unstructured":"Iadecola C; Yaffe K; Biller J; Impact of hypertension on cognitive function: a scientific statement from the American Heart Association. Hypertens (Dallas, Tex 1979) 2016,68,e67-94","journal-title":"Hypertens (Dallas, Tex 1979)"},{"key":"ref=28","first-page":"24","volume":"04","author":"Korolev I.O.","year":"2014","unstructured":"Korolev I.O.; Alzheimer \u2019s disease: a clinical and basic science review. Med Student Res J 2014,04,24-33","journal-title":"Med Student Res J"},{"key":"ref=29","author":"Hof P.R.","year":"2001","unstructured":"Hof P.R.; Mobbs C.V.; Functional neurobiology of aging 2001","journal-title":"Functional neurobiology of aging"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/0197-4580(95)02063-2","volume":"17","author":"Uno H.","year":"1996","unstructured":"Uno H.; Alsum P.B.; Dong S.; Cerebral amyloid angiopathy and plaques, and visceral amyloidosis in aged macaques. Neurobiol Aging 1996,17(2),275-281","journal-title":"Neurobiol Aging"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1007\/BF00294179","volume":"87","author":"Mackenzie I.R.A.","year":"1994","unstructured":"Mackenzie I.R.A.; Senile plaques do not progressively accumulate with normal aging. Acta Neuropathol 1994,87(5),520-525","journal-title":"Acta Neuropathol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"a006189","DOI":"10.1101\/cshperspect.a006189","volume":"1","author":"Serrano-Pozo A.","year":"2011","unstructured":"Serrano-Pozo A.; Frosch M.P.; Masliah E.; Hyman B.T.; Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 2011,1(1),a006189-a9","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2174\/1567205013666151218150322","volume":"13","author":"Vickers J.C.","year":"2016","unstructured":"Vickers J.C.; Mitew S.; Woodhouse A.; Defining the earliest pathological changes of Alzheimer\u2019s disease. Curr Alzheimer Res 2016,13(3),281-287","journal-title":"Curr Alzheimer Res"},{"key":"ref=34","first-page":"289","volume":"47","author":"Armstrong R.A.","year":"2009","unstructured":"Armstrong R.A.; The molecular biology of senile plaques and neurofibrillary tangles in Alzheimer\u2019s disease. Folia Neuropathol 2009,47(4),289-299","journal-title":"Folia Neuropathol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21767\/2171-6625.1000126","volume":"7","author":"Al Mamun A.","year":"2016","unstructured":"Al Mamun A.; Uddin M.S.; Wahid F.; Ashraful M.I.; Mosiqur R.M.; Neurodefensive effect of Olea europaea L. in alloxan-induced cognitive dysfunction and brain tissue oxidative stress in mice: incredible natural nootropic. J Neurol Neurosci 2016,7,1-9","journal-title":"J Neurol Neurosci"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"4925","DOI":"10.1007\/s12035-018-1420-2","volume":"56","author":"Uddin M.S.","year":"2019","unstructured":"Uddin M.S.; Al Mamun A.; Kabir M.T.; Nootropic and anti-Alzheimer\u2019s actions of medicinal plants: molecular insight into therapeutic potential to alleviate Alzheimer\u2019s neuropathology. Mol Neurobiol 2019,56(7),4925-4944","journal-title":"Mol Neurobiol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"Braak H.","year":"1991","unstructured":"Braak H.; Braak E.; Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991,82(4),239-259","journal-title":"Acta Neuropathol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/0304-3940(95)12083-G","volume":"200","author":"Fukutani Y.","year":"1995","unstructured":"Fukutani Y.; Kobayashi K.; Nakamura I.; Watanabe K.; Isaki K.; Cairns N.J.; Neurons, intracellular and extracellular neurofibrillary tangles in subdivisions of the hippocampal cortex in normal ageing and Alzheimer\u2019s disease. Neurosci Lett 1995,200(1),57-60","journal-title":"Neurosci Lett"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/ana.410410106","volume":"41","author":"G\u00f3mez-Isla T.","year":"1997","unstructured":"G\u00f3mez-Isla T.; Hollister R.; West H.; Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer\u2019s disease. Ann Neurol 1997,41(1),17-24","journal-title":"Ann Neurol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"8094","DOI":"10.1002\/jcp.27588","volume":"234","author":"Uddin M.S.","year":"2019","unstructured":"Uddin M.S.; Mamun A.A.; Labu Z.K.; Hidalgo-Lanussa O.; Barreto G.E.; Ashraf G.M.; Autophagic dysfunction in Alzheimer\u2019s disease: cellular and molecular mechanistic approaches to halt Alzheimer\u2019s pathogenesis. J Cell Physiol 2019,234(6),8094-8112","journal-title":"J Cell Physiol"},{"key":"ref=41","first-page":"65","volume":"162","author":"Munoz D.G.","year":"2000","unstructured":"Munoz D.G.; Feldman H.; Causes of Alzheimer\u2019s disease. CMAJ 2000,162(1),65-72","journal-title":"CMAJ"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"13993","DOI":"10.1038\/srep13993","volume":"5","author":"Su\u00e1rez-Pereira I.","year":"2015","unstructured":"Su\u00e1rez-Pereira I.; Carri\u00f3n \u00c1.M.; Updating stored memory requires adult hippocampal neurogenesis. Sci Rep 2015,5,13993","journal-title":"Sci Rep"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/0166-2236(82)90165-5","volume":"5","author":"Perry E.E.","year":"1982","unstructured":"Perry E.E.; Perry R.H.; The cholinergic system in Alzheimer\u2019s disease. Trends Neurosci 1982,5,261-262","journal-title":"Trends Neurosci"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1017\/S003329170004407X","volume":"10","author":"Bowen D.M.","year":"1980","unstructured":"Bowen D.M.; Davison A.N.; Biochemical changes in the cholinergic system of the ageing brain and in senile dementia. Psychol Med 1980,10(2),315-319","journal-title":"Psychol Med"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1136\/bmj.2.6150.1457","volume":"2","author":"Perry E.K.","year":"1978","unstructured":"Perry E.K.; Tomlinson B.E.; Blessed G.; Bergmann K.; Gibson P.H.; Perry R.H.; Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ 1978,2(6150),1457-1459","journal-title":"BMJ"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/BF00307630","volume":"80","author":"Ulrich J.","year":"1990","unstructured":"Ulrich J.; Meier-Ruge W.; Probst A.; Meier E.; Ipsen S.; Senile plaques: staining for acetylcholinesterase and A4 protein: a comparative study in the hippocampus and entorhinal cortex. Acta Neuropathol 1990,80(6),624-628","journal-title":"Acta Neuropathol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/ana.410100203","volume":"10","author":"Whitehouse P.J.","year":"1981","unstructured":"Whitehouse P.J.; Price D.L.; Clark A.W.; Coyle J.T.; DeLong M.R.; Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981,10(2),122-126","journal-title":"Ann Neurol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1097\/00005072-199808000-00001","volume":"57","author":"Ladner C.J.","year":"1998","unstructured":"Ladner C.J.; Lee J.M.; Pharmacological drug treatment of Alzheimer disease: the cholinergic hypothesis revisited. J Neuropathol Exp Neurol 1998,57(8),719-731","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1212\/WNL.57.3.481","volume":"57","author":"Mohs R.C.","year":"2001","unstructured":"Mohs R.C.; Doody R.S.; Morris J.C.; A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001,57(3),481-488","journal-title":"Neurology"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1001\/archneur.61.2.252","volume":"61","author":"Raskind M.A.","year":"2004","unstructured":"Raskind M.A.; Peskind E.R.; Truyen L.; Kershaw P.; Damaraju C.V.; The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch Neurol 2004,61(2),252-256","journal-title":"Arch Neurol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/978-3-7091-6139-5_17","author":"Giacobini E.","year":"2002","unstructured":"Giacobini E.; Long-term stabilizing effect of cholinesterase inhibitors in the therapy of Alzheimer\u2019 disease 2002,181-187","journal-title":"Long-term stabilizing effect of cholinesterase inhibitors in the therapy of Alzheimer\u2019 disease"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1358\/dot.2003.39.1.740206","volume":"39","author":"Rees T.M.","year":"2003","unstructured":"Rees T.M.; Brimijoin S.; The role of acetylcholinesterase in the pathogenesis of Alzheimer\u2019s disease. Drugs Today (Barc) 2003,39(1),75-83","journal-title":"Drugs Today (Barc)"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1001\/jama.1994.03510370037029","volume":"271","author":"Knapp M.J.","year":"1994","unstructured":"Knapp M.J.; Knopman D.S.; Solomon P.R.; Pendlebury W.W.; Davis C.S.; Gracon S.I.; A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer\u2019s disease. JAMA 1994,271(13),985-991","journal-title":"JAMA"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1212\/WNL.57.3.489","volume":"57","author":"Winblad B.","year":"2001","unstructured":"Winblad B.; Engedal K.; Soininen H.; A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001,57(3),489-495","journal-title":"Neurology"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1212\/WNL.54.12.2261","volume":"54","author":"Raskind M.A.","year":"2000","unstructured":"Raskind M.A.; Peskind E.R.; Wessel T.; Yuan W.; Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000,54(12),2261-2268","journal-title":"Neurology"},{"key":"ref=56","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001191.pub2","volume":"2","author":"Birks J.","year":"2009","unstructured":"Birks J.; Grimley Evans J.; Iakovidou V.; Rivastigmine for Alzheimer\u2019s disease. Cochrane Database Syst Rev 2009,2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2174\/1570159X11311030006","volume":"11","author":"Colovi\u0107 M.B.","year":"2013","unstructured":"Colovi\u0107 M.B.; Krsti\u0107 D.Z.; Lazarevi\u0107-Pa\u0161ti T.D.; Bond\u017ei\u0107 A.M.; Vasi\u0107 V.M.; Acetylcholinesterase inhibitors: pharmacology and toxicology. Curr Neuropharmacol 2013,11(3),315-335","journal-title":"Curr Neuropharmacol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1345\/aph.18211","volume":"33","author":"Krall W.J.","year":"1999","unstructured":"Krall W.J.; Sramek J.J.; Cutler N.R.; Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease. Ann Pharmacother 1999,33(4),441-450","journal-title":"Ann Pharmacother"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2165\/00002512-200421010-00004","volume":"21","author":"Boada-Rovira M.","year":"2004","unstructured":"Boada-Rovira M.; Brodaty H.; Cras P.; Efficacy and safety of donepezil in patients with Alzheimer\u2019s disease: results of a global, multinational, clinical experience study. Drugs Aging 2004,21(1),43-53","journal-title":"Drugs Aging"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4103\/0974-2700.44674","volume":"2","author":"Manteuffel J.","year":"2009","unstructured":"Manteuffel J.; Use of antiemetics in children with acute gastroenteritis: are they safe and effective? J Emerg Trauma Shock 2009,2(1),3-5","journal-title":"J Emerg Trauma Shock"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1742-1241.2002.tb11294.x","volume":"56","author":"Wilkinson D.G.","year":"2002","unstructured":"Wilkinson D.G.; Passmore A.P.; Bullock R.; A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer\u2019s disease. Int J Clin Pract 2002,56(6),441-446","journal-title":"Int J Clin Pract"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1046\/j.1365-2125.1999.00026.x","volume":"48","author":"McGleenon B.M.","year":"1999","unstructured":"McGleenon B.M.; Dynan K.B.; Passmore A.P.; Acetylcholinesterase inhibitors in Alzheimer\u2019s disease. Br J Clin Pharmacol 1999,48(4),471-480","journal-title":"Br J Clin Pharmacol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.scitotenv.2019.134836","volume":"134836","author":"Uddin M.S.","year":"2019","unstructured":"Uddin M.S.; Kabir M.T.; Tewari D.; Mathew B.; Aleya L.; Emerging signal regulating potential of small molecule biflavonoids to combat neuropathological insults of Alzheimer\u2019s disease. Sci Total Environ 2019,134836,1-11","journal-title":"Sci Total Environ"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00401-011-0849-4","volume":"122","author":"Kooi E-J.","year":"2011","unstructured":"Kooi E-J.; Prins M.; Bajic N.; Cholinergic imbalance in the multiple sclerosis hippocampus. Acta Neuropathol 2011,122(3),313-322","journal-title":"Acta Neuropathol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0896-6273(00)80108-7","volume":"16","author":"Inestrosa N.C.","year":"1996","unstructured":"Inestrosa N.C.; Alvarez A.; P\u00e9rez C.A.; Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer\u2019s fibrils: possible role of the peripheral site of the enzyme. Neuron 1996,16(4),881-891","journal-title":"Neuron"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S1074-5521(97)90303-3","volume":"4","author":"Harper J.D.","year":"1997","unstructured":"Harper J.D.; Lieber C.M.; Lansbury P.T.; Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer\u2019s disease amyloid-beta protein. Chem Biol 1997,4(12),951-959","journal-title":"Chem Biol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/0-387-23226-5_15","volume":"38","author":"Inestrosa N.C.","year":"2005","unstructured":"Inestrosa N.C.; Sagal J.P.; Colombres M.; Acetylcholinesterase interaction with Alzheimer amyloid beta. Subcell Biochem 2005,38,299-317","journal-title":"Subcell Biochem"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"301","DOI":"10.2174\/1567205054367928","volume":"2","author":"Inestrosa N.C.","year":"2005","unstructured":"Inestrosa N.C.; Alvarez A.; Dinamarca M.C.; P\u00e9rez-Acle T.; Colombres M.; Acetylcholinesterase-amyloid-beta-peptide interaction: effect of congo red and the role of the Wnt pathway. Curr Alzheimer Res 2005,2(3),301-306","journal-title":"Curr Alzheimer Res"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3389\/fnmol.2011.00019","volume":"4","author":"Carvajal F.J.","year":"2011","unstructured":"Carvajal F.J.; Inestrosa N.C.; Interactions of AChE with A\u03b2 Aggregates in Alzheimer\u2019s brain: therapeutic relevance of IDN 5706. Front Mol Neurosci 2011,4,19","journal-title":"Front Mol Neurosci"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1002\/ana.410360506","volume":"36","author":"Mesulam M.M.","year":"1994","unstructured":"Mesulam M.M.; Geula C.; Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann Neurol 1994,36(5),722-727","journal-title":"Ann Neurol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1136\/jnnp.66.2.137","volume":"66","author":"Francis P.T.","year":"1999","unstructured":"Francis P.T.; Palmer A.M.; Snape M.; Wilcock G.K.; The cholinergic hypothesis of Alzheimer\u2019s disease: a review of progress. J Neurol Neurosurg Psychiatry 1999,66(2),137-147","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1111\/j.1471-4159.1984.tb02801.x","volume":"42","author":"Perry E.K.","year":"1984","unstructured":"Perry E.K.; Atack J.R.; Perry R.H.; Intralaminar neurochemical distributions in human midtemporal cortex: comparison between Alzheimer\u2019s disease and the normal. J Neurochem 1984,42(5),1402-1410","journal-title":"J Neurochem"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1023\/A:1022869222652","volume":"28","author":"Giacobini E.","year":"2003","unstructured":"Giacobini E.; Cholinesterases: new roles in brain function and in Alzheimer\u2019s disease. Neurochem Res 2003,28(3-4),515-522","journal-title":"Neurochem Res"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1212\/WNL.59.4.563","volume":"59","author":"Darreh-Shori T.","year":"2002","unstructured":"Darreh-Shori T.; Almkvist O.; Guan Z.Z.; Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology 2002,59(4),563-572","journal-title":"Neurology"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1017\/S1041610203008676","volume":"14","author":"Greig N.H.","year":"2002","unstructured":"Greig N.H.; Lahiri D.K.; Sambamurti K.; Butyrylcholinesterase: an important new target in Alzheimer\u2019s disease therapy. Int Psychogeriatr 2002,14(Suppl. 1),77-91","journal-title":"Int Psychogeriatr"},{"key":"ref=76","first-page":"20","author":"R\u00f6sler M.","year":"2002","unstructured":"R\u00f6sler M.; The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia. Int J Clin Pract Suppl 2002(127),20-36","journal-title":"Int J Clin Pract Suppl"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s007020200089","volume":"109","author":"Giacobini E.","year":"2002","unstructured":"Giacobini E.; Spiegel R.; Enz A.; Veroff A.E.; Cutler N.R.; Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer\u2019s disease by rivastigmine: correlation with cognitive benefit. J Neural Transm (Vienna) 2002,109(7-8),1053-1065","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"719","DOI":"10.2165\/00003088-200241100-00003","volume":"41","author":"Jann M.W.","year":"2002","unstructured":"Jann M.W.; Shirley K.L.; Small G.W.; Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002,41(10),719-739","journal-title":"Clin Pharmacokinet"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejphar.2003.11.080","volume":"486","author":"Liston D.R.","year":"2004","unstructured":"Liston D.R.; Nielsen J.A.; Villalobos A.; Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer\u2019s disease. Eur J Pharmacol 2004,486(1),9-17","journal-title":"Eur J Pharmacol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000051227","volume":"11","author":"Maelicke A.","year":"2000","unstructured":"Maelicke A.; Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer\u2019s disease. Dement Geriatr Cogn Disord 2000,11(Suppl. 1),11-18","journal-title":"Dement Geriatr Cogn Disord"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s002130050931","volume":"143","author":"White H.K.","year":"1999","unstructured":"White H.K.; Levin E.D.; Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer\u2019s disease. Psychopharmacology (Berl) 1999,143(2),158-165","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=82","first-page":"6","author":"Poirier J.","year":"2002","unstructured":"Poirier J.; Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl 2002(127),6-19","journal-title":"Int J Clin Pract Suppl"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/0301-0082(91)90002-I","volume":"36","author":"Freeman S.E.","year":"1991","unstructured":"Freeman S.E.; Dawson R.M.; Tacrine: a pharmacological review. Prog Neurobiol 1991,36(4),257-277","journal-title":"Prog Neurobiol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/00002093-199806000-00007","volume":"12","author":"Gracon S.I.","year":"1998","unstructured":"Gracon S.I.; Knapp M.J.; Berghoff W.G.; Safety of tacrine: clinical trials, treatment IND, and postmarketing experience. Alzheimer Dis Assoc Disord 1998,12(2),93-101","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"ref=85","first-page":"8","volume":"21","author":"Conway E.L.","year":"1998","unstructured":"Conway E.L.; A review of the randomized controlled trials of tacrine in the treatment of Alzheimer\u2019s disease: methodologic considerations. Clin Neuropharmacol 1998,21(1),8-17","journal-title":"Clin Neuropharmacol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1159\/000106863","volume":"7","author":"Johansson M.","year":"1996","unstructured":"Johansson M.; Hellstr\u00f6m-Lindahl E.; Nordberg A.; Steady-state pharmacokinetics of tacrine in long-term treatment of Alzheimer patients. Dementia 1996,7(2),111-117","journal-title":"Dementia"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/BF00315027","volume":"38","author":"Hartvig P.","year":"1990","unstructured":"Hartvig P.; Askmark H.; Aquilonius S.M.; Wiklund L.; Lindstr\u00f6m B.; Clinical pharmacokinetics of intravenous and oral 9-amino-1,2,3,4-tetrahydroacridine, tacrine. Eur J Clin Pharmacol 1990,38(3),259-263","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1600-0447.1990.tb05345.x","volume":"360","author":"Guentert T.W.","year":"1990","unstructured":"Guentert T.W.; Tucker G.; Korn A.; Pfefen J.P.; Haefelfinger P.; Schoerlin M.P.; Pharmacokinetics of moclobemide after single and multiple oral dosing with 150 milligrams 3 times daily for 15 days. Acta Psychiatr Scand Suppl 1990,360,91-93","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2165\/00003088-199528060-00003","volume":"28","author":"Madden S.","year":"1995","unstructured":"Madden S.; Spaldin V.; Park B.K.; Clinical pharmacokinetics of tacrine. Clin Pharmacokinet 1995,28(6),449-457","journal-title":"Clin Pharmacokinet"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"465","DOI":"10.2165\/00002018-199819060-00004","volume":"19","author":"Nordberg A.","year":"1998","unstructured":"Nordberg A.; Svensson A-L.; Cholinesterase inhibitors in the treatment of Alzheimer\u2019s disease: a comparison of tolerability and pharmacology. Drug Saf 1998,19(6),465-480","journal-title":"Drug Saf"},{"key":"ref=91","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2165\/00003088-199936060-00004","volume":"36","author":"Zevin S.","year":"1999","unstructured":"Zevin S.; Benowitz N.L.; Drug interactions with tobacco smoking. Clin Pharmacokin 1999,36(6),425-438","journal-title":"Clin Pharmacokin"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"66","DOI":"10.2165\/00002018-199716010-00005","volume":"16","author":"Samuels S.C.","year":"1997","unstructured":"Samuels S.C.; Davis K.L.; A risk-benefit assessment of tacrine in the treatment of Alzheimer\u2019s disease. Drug Saf 1997,16(1),66-77","journal-title":"Drug Saf"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/bf03259636","volume":"5","author":"Wagstaff A.J.","year":"1994","unstructured":"Wagstaff A.J.; McTavish D.; Erratum to: Tacrine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer\u2019s disease. Drugs Aging 1994,5,95-5","journal-title":"Drugs Aging"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1001\/jama.1994.03510370044030","volume":"271","author":"Watkins P.B.","year":"1994","unstructured":"Watkins P.B.; Zimmerman H.J.; Knapp M.J.; Gracon S.I.; Lewis K.W.; Hepatotoxic effects of tacrine administration in patients with Alzheimer\u2019s disease. JAMA 1994,271(13),992-998","journal-title":"JAMA"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2165\/00002018-200326110-00006","volume":"26","author":"Francis G.S.","year":"2003","unstructured":"Francis G.S.; Grumser Y.; Alteri E.; Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance. Drug Saf 2003,26(11),815-827","journal-title":"Drug Saf"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"556","DOI":"10.5980\/jpnjurol1989.91.556","volume":"91","author":"Ikemoto I.","year":"2000","unstructured":"Ikemoto I.; Ohishi Y.; Yamazaki H.; Wada T.; Aizawa Y.; Changes in liver function induced by flutamide in patients with prostate cancer (studies in patients treated with total androgen blockage). Nippon Hinyokika Gakkai Zasshi 2000,91(6),556-561","journal-title":"Nippon Hinyokika Gakkai Zasshi"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/00042752-199901000-00007","volume":"9","author":"Dickerman R.D.","year":"1999","unstructured":"Dickerman R.D.; Pertusi R.M.; Zachariah N.Y.; Dufour D.R.; McConathy W.J.; Anabolic steroid-induced hepatotoxicity: is it overstated? Clin J Sport Med 1999,9(1),34-39","journal-title":"Clin J Sport Med"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1212\/WNL.50.1.136","volume":"50","author":"Rogers S.L.","year":"1998","unstructured":"Rogers S.L.; Farlow M.R.; Doody R.S.; Mohs R.; Friedhoff L.T.; A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer\u2019s disease. Neurology 1998,50(1),136-145","journal-title":"Neurology"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1159\/000017126","volume":"10","author":"Burns A.","year":"1999","unstructured":"Burns A.; Rossor M.; Hecker J.; The effects of donepezil in Alzheimer\u2019s disease - results from a multinational trial. Dement Geriatr Cogn Disord 1999,10(3),237-244","journal-title":"Dement Geriatr Cogn Disord"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1248\/bpb.18.1145","volume":"18","author":"Nochi S.","year":"1995","unstructured":"Nochi S.; Asakawa N.; Sato T.; Kinetic study on the inhibition of Acetylcholinesterase by 1-Benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine Hydrochloride (E2020). Biol Pharm Bull 1995,18,1145-1147","journal-title":"Biol Pharm Bull"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/0006-2952(90)90495-7","volume":"40","author":"Marquis J.K.","year":"1990","unstructured":"Marquis J.K.; Pharmacological significance of acetylcholinesterase inhibition by tetrahydroaminoacridine. Biochem Pharmacol 1990,40(5),1071-1076","journal-title":"Biochem Pharmacol"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2165\/00023210-200115050-00004","volume":"15","author":"Imbimbo B.P.","year":"2001","unstructured":"Imbimbo B.P.; Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer\u2019s disease. CNS Drugs 2001,15(5),375-390","journal-title":"CNS Drugs"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"234","DOI":"10.2165\/00002512-199710030-00007","volume":"10","author":"Bryson H.M.","year":"1997","unstructured":"Bryson H.M.; Benfield P.; Donepezil. Drugs Aging 1997,10(3),234-239","journal-title":"Drugs Aging"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0924-977X(97)00079-5","volume":"8","author":"Rogers S.L.","year":"1998","unstructured":"Rogers S.L.; Friedhoff L.T.; Long-term efficacy and safety of donepezil in the treatment of Alzheimer\u2019s disease: an interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 1998,8(1),67-75","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1345\/aph.17150","volume":"32","author":"Barner E.L.","year":"1998","unstructured":"Barner E.L.; Gray S.L.; Donepezil use in Alzheimer disease. Ann Pharmacother 1998,32(1),70-77","journal-title":"Ann Pharmacother"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.jalz.2011.11.005","volume":"9","author":"Gauthier S.","year":"2013","unstructured":"Gauthier S.; Molinuevo J.L.; Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer\u2019s disease. Alzheimers Dement 2013,9(3),326-331","journal-title":"Alzheimers Dement"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1007\/s11940-013-0261-6","volume":"15","author":"Boot B.P.","year":"2013","unstructured":"Boot B.P.; McDade E.M.; McGinnis S.M.; Boeve B.F.; Treatment of dementia with lewy bodies. Curr Treat Options Neurol 2013,15(6),738-764","journal-title":"Curr Treat Options Neurol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s10072-013-1290-3","volume":"34","author":"Clodomiro A.","year":"2013","unstructured":"Clodomiro A.; Gareri P.; Puccio G.; Somatic comorbidities and Alzheimer\u2019s disease treatment. Neurol Sci 2013,34(9),1581-1589","journal-title":"Neurol Sci"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2165\/00023210-199707020-00001","volume":"7","author":"Rainer M.","year":"1997","unstructured":"Rainer M.; Galanthamine in Alzheimer\u2019s disease: a new alternative to tacrine? CNS Drugs 1997,7(2),89-97","journal-title":"CNS Drugs"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1517\/13543784.9.10.2393","volume":"9","author":"Sramek J.J.","year":"2000","unstructured":"Sramek J.J.; Frackiewicz E.J.; Cutler N.R.; Review of the acetylcholinesterase inhibitor galanthamine. Expert Opin Investig Drugs 2000,9(10),2393-2402","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1055\/s-1999-13983","volume":"65","author":"Kim S.R.","year":"1999","unstructured":"Kim S.R.; Hwang S.Y.; Jang Y.P.; Protopine from corydalis ternata has anticholinesterase and antiamnesic activities. Planta Med 1999,65(3),218-221","journal-title":"Planta Med"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1358\/dot.1997.33.4.425052","volume":"33","author":"Kewitz H.","year":"1997","unstructured":"Kewitz H.; Pharmacokinetics and metabolism of galanthamine. Drugs Today (Barc) 1997,33,265","journal-title":"Drugs Today (Barc)"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1358\/dot.1997.33.4.425053","volume":"33","author":"Rainer M.","year":"1997","unstructured":"Rainer M.; Clinical studies with galanthamine. Drugs Today (Barc) 1997,33,273","journal-title":"Drugs Today (Barc)"},{"key":"ref=114","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/978-1-4612-4116-4_31","author":"Enz A.","year":"1997","unstructured":"Enz A.; Floersheim P.; Cholinesterase inhibitors: An overview of their mechanisms of action. Alzheimer Disease Birkh\u00e4user 1997,211-5","journal-title":"Alzheimer Disease Birkh\u00e4user"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/j.1600-0404.1998.tb00645.x","volume":"97","author":"Cutler N.R.","year":"1998","unstructured":"Cutler N.R.; Polinsky R.J.; Sramek J.J.; Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer\u2019s disease. Acta Neurol Scand 1998,97(4),244-250","journal-title":"Acta Neurol Scand"},{"key":"ref=116","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0079-6123(08)62429-2","volume":"98","author":"Enz A.","year":"1993","unstructured":"Enz A.; Amstutz R.; Boddeke H.; Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer\u2019s disease. Prog Brain Res 1993,98,431-438","journal-title":"Prog Brain Res"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2165\/00002512-199813050-00005","volume":"13","author":"Spencer C.M.","year":"1998","unstructured":"Spencer C.M.; Noble S.; Rivastigmine. A review of its use in Alzheimer\u2019s disease. Drugs Aging 1998,13(5),391-411","journal-title":"Drugs Aging"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1177\/2042098617750555","volume":"9","author":"Khoury R.","year":"2018","unstructured":"Khoury R.; Rajamanickam J.; Grossberg G.T.; An update on the safety of current therapies for Alzheimer\u2019s disease: focus on rivastigmine. Ther Adv Drug Saf 2018,9(3),171-178","journal-title":"Ther Adv Drug Saf"},{"key":"ref=119","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.14r01654","volume":"16","author":"Sadowsky C.H.","year":"2014","unstructured":"Sadowsky C.H.; Micca J.L.; Grossberg G.T.; Velting D.M.; Rivastigmine from capsules to patch: therapeutic advances in the management of Alzheimer\u2019s disease and Parkinson\u2019s disease dementia. Prim Care Companion CNS Disord 2014,16(5)","journal-title":"Prim Care Companion CNS Disord"},{"key":"ref=120","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001191.pub3","volume":"9","author":"Birks J.S.","year":"2015","unstructured":"Birks J.S.; Grimley Evans J.; Rivastigmine for Alzheimer\u2019s disease. Cochrane Database Syst Rev 2015,9","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"827","DOI":"10.2165\/00023210-200418130-00001","volume":"18","author":"Schmitt B.","year":"2004","unstructured":"Schmitt B.; Bernhardt T.; Moeller H-J.; Heuser I.; Fr\u00f6lich L.; Combination therapy in Alzheimer\u2019s disease: a review of current evidence. CNS Drugs 2004,18(13),827-844","journal-title":"CNS Drugs"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1185\/030079907X233403","volume":"23","author":"Small G.","year":"2007","unstructured":"Small G.; Dubois B.; A review of compliance to treatment in Alzheimer\u2019s disease: potential benefits of a transdermal patch. Curr Med Res Opin 2007,23(11),2705-2713","journal-title":"Curr Med Res Opin"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1185\/03007995.2010.493788","volume":"26","author":"Borah B.","year":"2010","unstructured":"Borah B.; Sacco P.; Zarotsky V.; Predictors of adherence among Alzheimer\u2019s disease patients receiving oral therapy. Curr Med Res Opin 2010,26(8),1957-1965","journal-title":"Curr Med Res Opin"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"154","DOI":"10.11622\/smedj.2018076","volume":"60","author":"Lum Z.K.","year":"2019","unstructured":"Lum Z.K.; Suministrado M.S.P.; Venketasubramanian N.; Ikram M.K.; Chen C.; Medication compliance in Singaporean patients with Alzheimer\u2019s disease. Singapore Med J 2019,60(3),154-160","journal-title":"Singapore Med J"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1080\/13607860500410011","volume":"10","author":"Ownby R.L.","year":"2006","unstructured":"Ownby R.L.; Hertzog C.; Crocco E.; Duara R.; Factors related to medication adherence in memory disorder clinic patients. Aging Ment Health 2006,10(4),378-385","journal-title":"Aging Ment Health"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3233\/JAD-170672","volume":"62","author":"Folch J.","year":"2018","unstructured":"Folch J.; Busquets O.; Ettcheto M.; Memantine for the treatment of dementia: a review on its current and future applications. J Alzheimers Dis 2018,62(3),1223-1240","journal-title":"J Alzheimers Dis"},{"key":"ref=127","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyu115","volume":"18","author":"Matsunaga S.","year":"2014","unstructured":"Matsunaga S.; Kishi T.; Iwata N.; Combination therapy with cholinesterase inhibitors and memantine for Alzheimer\u2019s disease: a systematic review and meta-analysis. Int J Neuropsychopharmacol 2014,18(5)","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s12640-013-9398-z","volume":"24","author":"Parsons C.G.","year":"2013","unstructured":"Parsons C.G.; Danysz W.; Dekundy A.; Pulte I.; Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer\u2019s disease. Neurotox Res 2013,24(3),358-369","journal-title":"Neurotox Res"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2004.05.005","volume":"51","author":"Sonkusare S.K.","year":"2005","unstructured":"Sonkusare S.K.; Kaul C.L.; Ramarao P.; Dementia of Alzheimer\u2019s disease and other neurodegenerative disorders-memantine, a new hope. Pharmacol Res 2005,51(1),1-17","journal-title":"Pharmacol Res"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/JCP.0b013e3181da5406","volume":"30","author":"Daiello L.A.","year":"2010","unstructured":"Daiello L.A.; Ott B.R.; Festa E.K.; Friedman M.; Miller L.A.; Heindel W.C.; Effects of cholinesterase inhibitors on visual attention in drivers with Alzheimer disease. J Clin Psychopharmacol 2010,30(3),245-251","journal-title":"J Clin Psychopharmacol"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1136\/bmj.332.7535.195","volume":"332","author":"Mayor S.","year":"2006","unstructured":"Mayor S.; NICE recommends drugs for moderate Alzheimer\u2019s disease. BMJ 2006,332(7535),195","journal-title":"BMJ"},{"key":"ref=132","first-page":"S1","volume":"11","author":"Cummings J.L.","year":"1997","unstructured":"Cummings J.L.; Changes in neuropsychiatric symptoms as outcome measures in clinical trials with cholinergic therapies for Alzheimer disease. Alzheimer Dis Assoc Disord 1997,11(Suppl. 4),S1-S9","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"251","DOI":"10.4088\/PCC.v05n0602","volume":"5","author":"Geldmacher D.S.","year":"2003","unstructured":"Geldmacher D.S.; Long-Term cholinesterase inhibitor therapy for Alzheimer\u2019s disease: practical considerations for the primary care physician. Prim Care Companion J Clin Psychiatry 2003,5(6),251-259","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.jalz.2017.02.005","volume":"13","author":"Rockwood K.","year":"2017","unstructured":"Rockwood K.; Howlett S.E.; Hoffman D.; Schindler R.; Mitnitski A.; Clinical meaningfulness of Alzheimer\u2019s disease assessment scale-cognitive subscale change in relation to goal attainment in patients on cholinesterase inhibitors. Alzheimers Dement 2017,13(10),1098-1106","journal-title":"Alzheimers Dement"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0011-393X(03)00059-6","volume":"64","author":"Grossberg G.T.","year":"2003","unstructured":"Grossberg G.T.; Cholinesterase inhibitors for the treatment of Alzheimer\u2019s disease: getting on and staying on. Curr Ther Res Clin Exp 2003,64(4),216-235","journal-title":"Curr Ther Res Clin Exp"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/WAD.0b013e3181f883b7","volume":"25","author":"Sano M.","year":"2011","unstructured":"Sano M.; Raman R.; Emond J.; Adding delayed recall to the Alzheimer disease assessment scale is useful in studies of mild cognitive impairment but not Alzheimer disease. Alzheimer Dis Assoc Disord 2011,25(2),122-127","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"ref=137","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1474-4422(03)00502-7","volume":"2","author":"Scarpini E.","year":"2003","unstructured":"Scarpini E.; Schelterns P.; Feldman H.; Treatment of Alzheimer\u2019s disease; current status and new perspectives. Lancet Neurol 2003,2,539-547","journal-title":"Lancet Neurol"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S1474-4422(07)70195-3","volume":"6","author":"Kavirajan H.","year":"2007","unstructured":"Kavirajan H.; Schneider L.S.; Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol 2007,6(9),782-792","journal-title":"Lancet Neurol"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/gerona\/58.4.M331","volume":"58","author":"Grossberg G.T.","year":"2003","unstructured":"Grossberg G.T.; Desai A.K.; Management of Alzheimer\u2019s disease. J Gerontol A Biol Sci Med Sci 2003,58(4),331-353","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/gps.4405","volume":"31","author":"Kobayashi H.","year":"2016","unstructured":"Kobayashi H.; Ohnishi T.; Nakagawa R.; Yoshizawa K.; The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer\u2019s disease: a Bayesian network meta-analysis. Int J Geriatr Psychiatry 2016,31(8),892-904","journal-title":"Int J Geriatr Psychiatry"},{"key":"ref=141","first-page":"569","volume":"3","author":"Hogan D.B.","year":"2007","unstructured":"Hogan D.B.; Progress update: pharmacological treatment of Alzheimer\u2019s disease. Neuropsychiatr Dis Treat 2007,3(5),569-578","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=142","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/ageing\/afj083","volume":"35","author":"L\u00f3pez-Pousa S.","year":"2006","unstructured":"L\u00f3pez-Pousa S.; Olmo J.G.; Franch J.V.; Comparative analysis of mortality in patients with Alzheimer\u2019s disease treated with donepezil or galantamine. Age Ageing 2006,35(4),365-371","journal-title":"Age Ageing"},{"key":"ref=143","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001190","author":"Birks J.","year":"2018","unstructured":"Birks J.; Harvey R.; Beppu H.; Donepezil for dementia due to Alzheimer\u2019s disease. Cochrane Database Syst Rev 2018(6)","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=144","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001747","author":"Olin J.","year":"2002","unstructured":"Olin J.; Schneider L.; Galantamine for Alzheimer\u2019s disease. Cochrane Database Syst Rev 2002(3)","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1212\/WNL.57.4.613","volume":"57","author":"Feldman H.","year":"2001","unstructured":"Feldman H.; Gauthier S.; Hecker J.; Vellas B.; Subbiah P.; Whalen E.; A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer\u2019s disease. Neurology 2001,57(4),613-620","journal-title":"Neurology"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"145","DOI":"10.7556\/JAOA.2005.105.3.145","volume":"105","author":"Ellis J.M.","year":"2005","unstructured":"Ellis J.M.; Cholinesterase inhibitors in the treatment of dementia. J Am Osteopath Assoc 2005,105(3),145-158","journal-title":"J Am Osteopath Assoc"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/ijnp\/pyx012","volume":"20","author":"Blanco-Silvente L.","year":"2017","unstructured":"Blanco-Silvente L.; Castells X.; Saez M.; Discontinuation, efficacy, and safety of cholinesterase inhibitors for Alzheimer\u2019s disease: a meta-analysis and meta-regression of 43 randomized clinical trials enrolling 16 106 patients. Int J Neuropsychopharmacol 2017,20(7),519-528","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=148","first-page":"211","volume":"3","author":"Hansen R.A.","year":"2008","unstructured":"Hansen R.A.; Gartlehner G.; Webb A.P.; Morgan L.C.; Moore C.G.; Jonas D.E.; Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer\u2019s disease: a systematic review and meta-analysis. Clin Interv Aging 2008,3(2),211-225","journal-title":"Clin Interv Aging"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"465","DOI":"10.2165\/00002018-199819060-00004","volume":"19","author":"Nordberg A.","year":"1998","unstructured":"Nordberg A.; Svensson A-L.; Cholinesterase inhibitors in the treatment of Alzheimer\u2019s disease: a comparison of tolerability and pharmacology. Drug Saf 1998,19(6),465-480","journal-title":"Drug Saf"},{"key":"ref=150","first-page":"27","volume":"5","author":"Alva G.","year":"2008","unstructured":"Alva G.; Cummings J.L.; Relative tolerability of Alzheimer\u2019s disease treatments. Psychiatry (Edgmont Pa) 2008,5(11),27-36","journal-title":"Psychiatry (Edgmont Pa)"},{"key":"ref=151","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.archger.2004.04.040","volume":"2004","author":"Mossello E.","year":"2004","unstructured":"Mossello E.; Tonon E.; Caleri V.; Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer\u2019s disease: a\u201d real world\u201d study. Arch Gerontol Geriatr Suppl 2004,2004(9),297-307","journal-title":"Arch Gerontol Geriatr Suppl"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"465","DOI":"10.2165\/00002018-199819060-00004","volume":"19","author":"Nordberg A.","year":"1998","unstructured":"Nordberg A.; Svensson A-L.; Cholinesterase inhibitors in the treatment of Alzheimer\u2019s disease: a comparison of tolerability and pharmacology. Drug Saf 1998,19(6),465-480","journal-title":"Drug Saf"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.drudis.2013.01.008","volume":"18","author":"Medina-Franco J.L.","year":"2013","unstructured":"Medina-Franco J.L.; Giulianotti M.A.; Welmaker G.S.; Houghten R.A.; Shifting from the single to the multitarget paradigm in drug discovery. Drug Discov Today 2013,18(9-10),495-501","journal-title":"Drug Discov Today"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.4155\/fmc-2016-0103","volume":"8","author":"Santos M.A.","year":"2016","unstructured":"Santos M.A.; Chand K.; Chaves S.; Recent progress in repositioning Alzheimer\u2019s disease drugs based on a multitarget strategy. Future Med Chem 2016,8(17),2113-2142","journal-title":"Future Med Chem"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/ardp.201300074","volume":"346","author":"Chen Y.","year":"2013","unstructured":"Chen Y.; Sun J.; Peng S.; Liao H.; Zhang Y.; Lehmann J.; Tacrine-flurbiprofen hybrids as multifunctional drug candidates for the treatment of Alzheimer\u2019s disease. Arch Pharm (Weinheim) 2013,346(12),865-871","journal-title":"Arch Pharm (Weinheim)"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1124\/mol.105.015206","volume":"69","author":"Joo Y.","year":"2006","unstructured":"Joo Y.; Kim H-S.; Woo R-S.; Mefenamic acid shows neuroprotective effects and improves cognitive impairment in in vitro and in vivo Alzheimer\u2019s disease models. Mol Pharmacol 2006,69(1),76-84","journal-title":"Mol Pharmacol"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1039\/c0md00256a","volume":"2","author":"Bornstein J.J.","year":"2011","unstructured":"Bornstein J.J.; Eckroat T.J.; Houghton J.L.; Tacrine-mefenamic acid hybrids for inhibition of acetylcholinesterase. MedChemComm 2011,2,406","journal-title":"MedChemComm"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.ejmech.2013.01.039","volume":"62","author":"Lu C.","year":"2013","unstructured":"Lu C.; Zhou Q.; Yan J.; Du Z.; Huang L.; Li X.; A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer\u2019s disease. Eur J Med Chem 2013,62,745-753","journal-title":"Eur J Med Chem"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.1007\/s00044-014-0931-2","volume":"23","author":"Hui A.","year":"2014","unstructured":"Hui A.; Chen Y.; Zhu S.; Design and synthesis of tacrine-phenothiazine hybrids as multitarget drugs for Alzheimer\u2019s disease. Med Chem Res 2014,23,3546-3557","journal-title":"Med Chem Res"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1750-1326-5-45","volume":"5","author":"O\u2019Leary J.C.","year":"2010","unstructured":"O\u2019Leary J.C.; Li Q.; Marinec P.; Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden. Mol Neurodegener 2010,5,45","journal-title":"Mol Neurodegener"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.1016\/j.bmcl.2012.04.029","volume":"22","author":"Meng F-C.","year":"2012","unstructured":"Meng F-C.; Mao F.; Shan W-J.; Qin F.; Huang L.; Li X.S.; Design, synthesis, and evaluation of indanone derivatives as acetylcholinesterase inhibitors and metal-chelating agents. Bioorg Med Chem Lett 2012,22(13),4462-4466","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/j.bmc.2008.12.067","volume":"17","author":"Zhu Y.","year":"2009","unstructured":"Zhu Y.; Xiao K.; Ma L.; Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and \u03b2-secretase. Bioorg Med Chem 2009,17(4),1600-1613","journal-title":"Bioorg Med Chem"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"8251","DOI":"10.1021\/jm200853t","volume":"54","author":"Bolea I.","year":"2011","unstructured":"Bolea I.; Ju\u00e1rez-Jim\u00e9nez J.; de Los R\u00edos C.; Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase\/monoamine oxidase inhibitors for the treatment of Alzheimer\u2019s disease. J Med Chem 2011,54(24),8251-8270","journal-title":"J Med Chem"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s00702-012-0948-y","volume":"120","author":"Bolea I.","year":"2013","unstructured":"Bolea I.; Gella A.; Unzeta M.; Propargylamine-derived multitarget-directed ligands: fighting Alzheimer\u2019s disease with monoamine oxidase inhibitors. J Neural Transm (Vienna) 2013,120(6),893-902","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0968-0896(98)00133-3","volume":"6","author":"Mary A.","year":"1998","unstructured":"Mary A.; Renko D.Z.; Guillou C.; Thal C.; Potent acetylcholinesterase inhibitors: design, synthesis, and structure-activity relationships of bis-interacting ligands in the galanthamine series. Bioorg Med Chem 1998,6(10),1835-1850","journal-title":"Bioorg Med Chem"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.ejmech.2008.04.018","volume":"44","author":"Jia P.","year":"2009","unstructured":"Jia P.; Sheng R.; Zhang J.; Design, synthesis and evaluation of galanthamine derivatives as acetylcholinesterase inhibitors. Eur J Med Chem 2009,44(2),772-784","journal-title":"Eur J Med Chem"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"600","DOI":"10.2174\/156720512800618044","volume":"9","author":"Vezenkov L.","year":"2012","unstructured":"Vezenkov L.; Sevalle J.; Danalev D.; Galantamine-based hybrid molecules with acetylcholinesterase, butyrylcholinesterase and \u03b3-secretase inhibition activities. Curr Alzheimer Res 2012,9(5),600-605","journal-title":"Curr Alzheimer Res"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0223-5234(01)01324-1","volume":"37","author":"Mustazza C.","year":"2002","unstructured":"Mustazza C.; Borioni A.; Del Giudice M.R.; Synthesis and cholinesterase activity of phenylcarbamates related to Rivastigmine, a therapeutic agent for Alzheimer\u2019s disease. Eur J Med Chem 2002,37(2),91-109","journal-title":"Eur J Med Chem"},{"key":"ref=169","doi-asserted-by":"crossref","first-page":"5260","DOI":"10.1021\/jm020120c","volume":"45","author":"Sterling J.","year":"2002","unstructured":"Sterling J.; Herzig Y.; Goren T.; Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer\u2019s disease. J Med Chem 2002,45(24),5260-5279","journal-title":"J Med Chem"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"4389","DOI":"10.1016\/S0968-0896(03)00452-8","volume":"11","author":"Toda N.","year":"2003","unstructured":"Toda N.; Tago K.; Marumoto S.; A conformational restriction approach to the development of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer\u2019s disease. Bioorg Med Chem 2003,11(20),4389-4415","journal-title":"Bioorg Med Chem"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2174\/1567205054367829","volume":"2","author":"Greig N.H.","year":"2005","unstructured":"Greig N.H.; Sambamurti K.; Yu Q.S.; Brossi A.; Bruinsma G.B.; Lahiri D.K.; An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer\u2019s disease. Curr Alzheimer Res 2005,2(3),281-290","journal-title":"Curr Alzheimer Res"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"5945","DOI":"10.1021\/jm049782n","volume":"47","author":"Bolognesi M.L.","year":"2004","unstructured":"Bolognesi M.L.; Bartolini M.; Cavalli A.; Design, synthesis, and biological evaluation of conformationally restricted rivastigmine analogues. J Med Chem 2004,47(24),5945-5952","journal-title":"J Med Chem"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/175425","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T11:40:08Z","timestamp":1695296408000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/175425\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,19]]},"references-count":172,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2019,11,19]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612825666191008103141","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11,19]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-08-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}